CA
NZ
UK
AU
IND
US
Two items explain why profit growth did not reach the per-share line. Shares outstanding rose to 39.64 million from 39.08 million at year-end, and the filing shows common shares issued through an at-the-market program during the first half. Income tax expense was USD 14.8 …
The Centurion longwall hit more faulting than expected late in the quarter. It shipped 0.58 million tons in the third quarter but produced only about 45,000 tons in October, and fourth-quarter sales are guided to 0.3 million to 0.5 million tons. Peabody plans a …
GrossMarginas a share of gross billings slipped to 3.0% from 3.3%. Workers' compensation expense rose to 2.4% of gross billings from 2.2%, and favorable prior-yearLiabilityand premium adjustments shrank to USD 0.8 million from USD 3.9 million. Benefit costs also rose, to 1.3% of gross …
GrossMarginwas 73%, level with the prior-year quarter.Net Incomewas USD 14.2 million against USD 5.1 million, and adjusted EBITDA was USD 25.2 million against USD 17.0 million, lifting the margin to 30% from 25% as revenue growth spread over a mostlyFixed Costbase, the usualOperating Leveragein …
Recorlev, a treatment for Cushing's syndrome, generated USD 71.5 million, up 93%, and is now the main growth engine. Gvoke, the ready-to-use glucagon, fell 14% to USD 21.7 million, a decline that included a one-time gross-to-net adjustment of about USD 4 million, which is …
Profit grew much faster than revenue because the sales mix moved toward ASCENIV, which commands higher pricing, while BIVIGAM, an older immune globulin, fell 35% to USD 15.4 million. Adjusted EBITDA, which excludes interest, taxes,Depreciationand certain non-cash items, is the figure management uses to …
Baird Medical describes itself as a medical device company focused on minimally invasive microwave ablation. Its lead system is cleared by the United States Food and Drug Administration for soft tissue ablation and is being introduced in the United States mainly for benign thyroid …
Operating metrics were solid. Comparable RevPAR of USD 284 was the second-highest third-quarter figure in company history, and comparable Hotel EBITDAMarginwidened 122 basis points to 13.6%. Urban properties saw RevPAR climb 23.3% and Hotel EBITDA rise 63.2% to USD 10.1 million. Resort properties lifted …
The filing explains that on March 27, 2026 the US Court of Appeals for the Second Circuit reversed the judgment in favor of Petersen and Eton Park in the YPF-related assets, and theBalance SheetFair Valueof thoseAssetswas significantly reduced. Capital provision assets fell to USD …
Net sales were USD 656.4 million, up 0.5% or about 0.7% on a currency-neutral basis. Clinical Diagnostics sales rose 2.7% to USD 401.8 million on quality systems and diabetes products, while Life Science sales fell 2.8% to USD 254.6 million on lower process chromatography …
Please wait processing your request...